- Advertisement -
Monash University spin-out Rage Biotech has raised $29 million in a Series A funding round, supporting plans to secure first-in-human clinical trials for its novel therapies that target chronic inflammatory disease.
The funding round was led by IP Group Australia and Hostplus with continued…
Click here to view the original article.
